Firefly Neuroscience, Inc.
AIFF
$1.08
$0.000.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 320.33% | 1,039.57% | 957.41% | 958.11% | 568.75% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 320.33% | 1,039.57% | 957.41% | 958.11% | 568.75% |
| Cost of Revenue | 3,888.00% | -- | -- | -- | -- |
| Gross Profit | 99.01% | 492.09% | 497.22% | 597.30% | 529.69% |
| SG&A Expenses | -12.38% | -7.06% | 5.24% | 15.72% | 151.37% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -2.90% | -2.03% | 4.40% | 15.00% | 136.75% |
| Operating Income | 16.04% | 16.29% | 6.81% | -6.48% | -130.70% |
| Income Before Tax | 60.12% | 59.80% | -90.07% | -173.27% | -455.23% |
| Income Tax Expenses | -83.33% | 150.00% | 150.00% | 500.00% | 500.00% |
| Earnings from Continuing Operations | 60.12% | 59.78% | -90.08% | -173.31% | -455.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 60.12% | 59.78% | -90.08% | -173.31% | -455.24% |
| EBIT | 16.04% | 16.29% | 6.81% | -6.48% | -130.70% |
| EBITDA | 17.05% | 17.63% | -4.23% | -21.52% | -201.93% |
| EPS Basic | 78.79% | 77.89% | -52.11% | -85.40% | -215.25% |
| Normalized Basic EPS | 74.39% | 73.44% | -18.80% | -34.22% | -142.10% |
| EPS Diluted | 78.79% | 77.89% | -52.11% | -85.40% | -215.25% |
| Normalized Diluted EPS | 74.39% | 73.44% | -18.80% | -34.22% | -142.10% |
| Average Basic Shares Outstanding | 66.41% | 81.04% | 90.02% | 111.91% | 116.37% |
| Average Diluted Shares Outstanding | 66.41% | 81.04% | 90.02% | 111.91% | 116.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |